Pfizer PT receives Investment Bank Analyst Rating Update
By Davit Kirakosyan Citi lowered the price target on McDonald’s (NYSE:MCD) to $277.00 from $279.00 while maintaining a Neutral rating. McDonald's reported its Q4 results...
By Sam Boughedda After a dip earlier in the session, AbbVie (NYSE:ABBV) shares are now slightly up on the day, holding steady, despite Amgen (NASDAQ:AMGN) announcing AMJEVITA, a...
2022. Earnings per share came in at $1.14, versus the expected $1.05.The reported revenue of $24.29 billion represents growth of 7.30% compared to the previous quarter, and growth...
Pfizer Stumbles As Vaccine Demand Expected To Slide Pfizer Inc shares slid as much as 3.5% in premarket trading (before bouncing back) after the company forecasted COVID-19 vaccine...
Pfizer came out with quarterly earnings of $1.14 per share.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
|Average||54.300 (+22.962% Upside)|
|No. of Analysts||20|